First‐trimester ADAM12 and PAPP‐A as markers for intrauterine fetal growth restriction through their roles in the insulin‐like growth factor system
Open Access
- 5 February 2007
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (3), 264-271
- https://doi.org/10.1002/pd.1665
Abstract
Background PAPP-A is a marker used as part of the most effective method of screening for chromosomal anomalies in the first trimester. ADAM12 is a recently discovered pregnancy associated member of the ADAM (a multidomain glycoprotein metalloprotease) family. Recently, ADAM12 has been shown as a potential marker for early screening for chromosomal anomalies. Both PAPP-A and ADAM12 have been identified as proteases to insulin-like growth factor binding proteins. In this role, they may have a regulatory function in controlling the amount of free bioactive insulin-like growth factor (IGF). We therefore wish to examine if the levels of either of these proteases are related to various growth related adverse pregnancy outcomes. Materials and Methods PAPP-A and ADAM12 were measured in a subset of samples collected at 11 to 14 weeks as part of an OSCAR clinic screening for chromosomal anomalies. Follow-up of pregnancies screened between September 1999 and August 2003 identified 1705 pregnancies with an outcome of intrauterine fetal demise on or after 24 weeks, preterm delivery at 24–34 weeks or 35–36 weeks, very low birthweight (t-test of unequal variance between the control group and the various adverse outcome groups. Results ADAM12 and PAPP-A concentrations were reduced in low for gestational age birth weights and in all births with weights below 2.5 kg. There was a linear relationship between the severity of the IUGR and the decrease in PAPP-A and ADAM12. In the larger babies, only ADAM12 was found to be significantly increased in babies above the 90th centile of weight for gestation. Conclusions The results of our study are compatible with the proposed role of ADAM12 and PAPP-A in promoting growth and development by breaking down IGF binding proteins and causing the release of free IGF for uptake into cells to promote growth. In those cases that eventually result in poor fetal growth, levels of PAPP-A and ADAM12 at 11–14 weeks are significantly lower than normal—in this instance, lowered PAPP-A and ADAM12 would result in less free IGF being available for cell uptake and growth stimulation. Further studies may elucidate if screening using such modalities can lead to new potential treatments for poorly growing fetuses. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 45 references indexed in Scilit:
- First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal deathUltrasound in Obstetrics & Gynecology, 2006
- First-trimester maternal serum levels of placental hormones are independent predictors of second-trimester fetal growth parametersUltrasound in Obstetrics & Gynecology, 2006
- The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18Prenatal Diagnosis, 2005
- Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomesAmerican Journal of Obstetrics and Gynecology, 2004
- First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial)American Journal of Obstetrics and Gynecology, 2004
- The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancyPrenatal Diagnosis, 2004
- Predicting complications of pregnancy with first‐trimester maternal serum free‐βhCG, PAPP‐A and inhibin‐APrenatal Diagnosis, 2003
- Maternal weight correction of maternal serum PAPP‐A and free β‐hCG MoM when screening for trisomy 21 in the first trimester of pregnancyPrenatal Diagnosis, 2003
- ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and Is Inhibited by TIMP-3Biochemical and Biophysical Research Communications, 2000
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999